Keytruda

Step closer race run
Biotech

Immutep's LAG-3 agent posts 'impressive' survival data

Immutep suggests that a high unmet need for first-line, PD-L1-negative HNSCC could potentially pave eftilagimod a path to approval.
Angus Liu May 5, 2025 10:37am
Flexibility and adaptation concept Arrows on cubes following a flexible path

'One of the lucky few': Bicara CEO on last year's $326M IPO

Apr 14, 2025 3:59pm
share price stock stock price shares falling falling

Pyxis' shares fall on lukewarm early ADC results in solid tumors

Nov 21, 2024 2:30pm
Graphic of arrows missing the target

Merck's LAG-3 combo fails colorectal cancer phase 3 study

Sep 25, 2024 8:35am
Male and female superheroes posing in fluttering cloaks

ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial

Sep 14, 2024 2:30am
long shot miss basketball hoop fail shoot

Merck stops phase 3 TIGIT trial in lung cancer for futility

Aug 8, 2024 7:49am